Development and validation of an immune-related gene prognostic index for lung adenocarcinoma
Zitao Liu(New Hope Fertility Center), Tingdong Yu(Kunming Medical University), Yujin Kudo(Tokyo Medical University), Junting Shen(Kunming Medical University), Xi Wang(Westlake University), Yutian Wang(Kunming Medical University), Guangqiang Zhao(Kunming Medical University), Yunchao Huang(North China University of Water Resources and Electric Power), Yujie Lei(Nanjing University of Information Science and Technology), Jun Liao(Kunming Medical University)
Cited by 2
Related Papers
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey
|Lung Cancer|2018|134
Novel MIL-88B(Fe)/ZnTi-LDH high-low junctions for adsorption and photodegradation of tetracycline: Characteristics, performance, and mechanisms
|Chemical Engineering Journal|2023|111